BSE filing, NSE: SENORES. Summary written from the filing by ALFA Finder's alert engine.
Senores Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,294.80
- Market cap
- ₹5,963 Cr
- Revenue (annual)
- ₹632.6 Cr
- Net profit (annual)
- ₹115.4 Cr
- P/E (TTM)
- 47.2×Sector 46.1×
- Promoter holding
- 45.82%+0.00% QoQ
- FII holding
- 6.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Senores Pharmaceuticals Ltd
All →Senores Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹192.3 Cr (+24.9%), EBITDA ₹57.7 Cr (+38.3%, 30.0% margin), PAT ₹36.6 Cr. H1 revenue +30%, EBITDA +58.2%.
Senores Pharmaceuticals Results Update
Senores reported Q2 FY27 revenue of ₹192 cr and EBITDA of ₹58 cr, both record highs. PAT grew 22% Y-o-Y to ₹37 cr with positive FY27 outlook.
Senores Pharmaceuticals Capacity Expansion: ₹43 Cr Investment
Senores Pharmaceuticals disclosed capacity expansion at three subsidiaries with total estimated cost of ₹43 Crore. Expansions adding ~1.5 Bn units/annum are expected by March 2027.
- Value
- ₹43.00 Cr
- Execution
- By end of March 2027
- manufacturing capacity addition (per annum)
- 1502.7 Mn units
Senores Pharmaceuticals Q2 FY27 Results: Net Profit ₹36.6 Cr, Up 21.6% YoY
Senores Pharmaceuticals Ltd reported revenue from operations of ₹192.3 Cr (+25.0% YoY) and net profit of ₹36.6 Cr (+21.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹36.6 Cr · +21.6% YoY
Senores Pharmaceuticals Annual General Meeting
Senores Pharmaceuticals Limited has issued a Postal Ballot Notice seeking shareholder approval for the re-appointment of its Managing Director and Whole Time Director. The e-voting period concludes on November 17, 2026.
Senores Pharmaceuticals Management Change
Senores Pharmaceuticals re-appointed Swapnil Shah as MD and Chetan Shah as WTD for three-year terms. Both appointments are subject to shareholder approval via postal ballot.
Other board meeting date announcements
All →Prime Fresh Board Meeting Date
Prime Fresh scheduled its Board meeting for 06 November 2026 to approve unaudited Q1 and H1 results. Trading window closed from 01 October 2026.
Pokarna Board Meeting Date
Pokarna Ltd intimated that its Board meets on 03 Nov 2026 to consider unaudited Q1 and H1 FY27 results. The trading window stays closed till 05 Nov 2026.
Mahaveer Infoway Board Meeting Date
Mahaveer Infoway Ltd scheduled a board meeting for 3 Nov 2026 to approve Q1 FY27 unaudited results and the limited review report. This is a routine prior intimation under Reg 29(1)(a).
Indowind Energy Board Meeting Date
Indowind Energy scheduled a board meeting on 5 Nov 2026 to approve Q1 FY27 unaudited results. The trading window remains closed until 48 hours post-approval.
Dhunseri Ventures Board Meeting Date
Dhunseri Ventures Ltd intimated that its Board will meet on 6 November 2026, inter alia to approve Q2 FY27 results. The trading window stays closed until 8 November 2026.
CESC Board Meeting Date
CESC Ltd scheduled its Board Meeting for 5 Nov 2026 to consider Q2/H1 FY27 unaudited results. No financial figures or decisions are reported in this advance intimation.